<DOC>
	<DOCNO>NCT00268710</DOCNO>
	<brief_summary>Primary objective : - To determine response rate , measurable non measurable , Taxotere® second line set . Secondary objective : - To evaluate overall safety toxicity Taxotere®/prednisone combination second line therapy HRPC - To evaluate PSA response ( PSA : Prostate Specific Antigen ) - To evaluate symptomatic response - To evaluate Quality life - To evaluate patient safety weekly versus q3 weekly regimen Taxotere® .</brief_summary>
	<brief_title>Docetaxel Hormone Refractory Prostate Cancer ( HRPC ) Weekly 3weekly TAX + Prednisone HRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically/cytologically proven prostate adenocarcinoma Progression non response previous chemotherapy regimen ( exclude Taxotere® ) Received previous mitoxantrone/prednisone one chemotherapy regimen include emcyt +/ vinblastine Castration level testosterone ( &lt; 50 ng/dL ) ECOG performance status 02 Laboratory requirement : 1 . Hematology : Neutrophils ≥ 1.5 x 10^9/L Hemoglobin &gt; 10 g/dL ( prior transfusion permit ) . Platelets ≥ 100 x 10^9/L 2 . Hepatic function : Total bilirubin &lt; uppernormal limit institution . ALAT ( SGPT ) ASAT ( SGOT ) ≤ 1.5 time uppernormal limit institution . 3 . Renal function : Creatinine ≤1.5 time upper normal limit ( i.e. , NCI grade ≤1 ) No severe uncontrolled disease Exclusion Criteria Chemotherapy within last 4 week Antiandrogen therapy within last 4 week . Prior malignancy except follow : adequately treat nonmelanomatous skin cancer superficial bladder cancer patient diseasefree &gt; 2 year . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen . Treatment anticancer therapy ( except LHRH agonist ) include prescribed compound and/or OTC product treatment prostate cancer must stop prior study entry . Other serious illness , psychiatric medical condition would permit patient manage accord protocol include active uncontrolled infection significant cardiac dysfunction .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>